UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 1200 Page Mill Road (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | K | | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | | Corporate Presentation | | | | | | | | | | | March 2023 | | | | | | | | KODIAK Our 24 / 7 / 365 KODIAK in the real world as in published clinical studies, because frequent dosing is no ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (S ...

| --- | --- | |---------------------------------------------------------------------------------------------------------|-------| | | | | | | | KSI-301 Anti-VEGF Antibody Biopolymer Conjugate for Retinal Vein Occlusion: | | | Primary 24-Week Efficacy and Safety Outcomes of the BEACON Phase 3 Pivotal Study | | | Arshad M. Khanani, M.D., M.A., FASRS Director of Clinical Research, Sierra Eye Associates, Reno, NV USA | | | on behalf of the BEACON Study Group | | 2 September 2022 Disclosures | --- | --- | |----- ...

NASDAQ: KOD KODIAK.COM | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | KO | | | | | | | | | | | THE OPHTHALMOLOGY MEDICINES COMPANY | | | | | | | | | | Corporate Presentation | | | | | | | | | | August 2022 | | | | | | | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Financial Position - Kodiak Sciences has $671.7 million in cash and cash equivalents as of March 31, 2022[67]. - As of March 31, 2022, the company had cash and cash equivalents of $671.7 million, which is expected to be sufficient for at least the next 12 months[97][98]. - The company has an accumulated deficit of $653.9 million as of March 31, 2022, indicating ongoing financial challenges[98]. - Net cash used in operating activities was $43.2 million for the three months ended March 31, 2022, compared to $34.6 million in the same period of 2021[106]. - The company incurred net cash used in investing activities of $18.3 million for the three months ended March 31, 2022, mainly for property and equipment purchases[107]. - The company has not generated any product revenue to date and does not expect to do so until regulatory approval and commercialization of its product candidates[100]. Clinical Trials and Research - KSI-301 is being investigated in five registrational clinical trials targeting high-prevalence retinal diseases[65]. - The BEACON study for KSI-301 has enrolled over 550 patients and expects to announce top-line data in August 2022[71]. - GLEAM and GLIMMER studies have enrolled approximately 450 patients each and expect to announce top-line data in mid-2023[72]. - The DAYLIGHT study has completed enrollment of approximately 550 patients and expects to announce top-line data in mid-2023[73]. - KSI-501 is targeting a group estimated to be 30% of treated patients who are suboptimal anti-VEGF responders[66]. - Kodiak plans to submit an IND for KSI-501 in the second half of 2022[78]. - The overall rate of missed study visits across ongoing studies remains less than 5%[80]. Expenses and Losses - For the three months ended March 31, 2022, the company reported a net loss of $95.7 million, compared to a net loss of $50.4 million for the same period in 2021, representing an increase in losses of $45.3 million[90]. - Research and development expenses totaled $76.2 million for the three months ended March 31, 2022, up from $40.3 million in 2021, marking a 88.8% increase[91]. - KSI-301 program expenses increased by $17.2 million to $40.7 million in Q1 2022, primarily due to clinical trial costs and manufacturing progress[92]. - Payroll and personnel expenses rose by $11.6 million to $21.2 million in Q1 2022, largely driven by increased stock-based compensation[94]. - General and administrative expenses are expected to increase due to higher personnel costs and compliance-related expenses[87]. - General and administrative expenses increased by $9.4 million to $19.6 million in Q1 2022, primarily due to stock-based compensation[96].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State or other jurisdiction of FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 ...

KODIAK.COM NASDAQ: KOD THE OPHTHALMOLOGY MEDICINES COMPANY January 2022 1 S P E C I A L N O T E R E G A R D I N G | --- ...